Correction

This article refers to:

Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)

Article title: Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia

B (congenital factor IX deficiency)

Authors: Sekayan, T., Simmons, D. H., & von Drygalski, A.

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY

Bibliometrics: Volume 23, Number 12, pages 1173–1184

DOI: https://doi.org/10.1080/14712598.2023.2282138

When this article was published in an issue, there was missing content. The missing content has now included on pages 1174 and 1175 in the updated version, which is now published online.

The missing content is from “An obvious disadvantage of factor … ” in page 1174 to “ … developed by Pfizer (BENEGENE-2 study [NCT03861273])” in page 1175.